Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GSK, Arecor sign vaccine-based license agreement
August 2011
SHARING OPTIONS:

CAMBRIDGE, EnglandóGlaxoSmithKline PLC and Arecor Ltd., a company focused on providing formulation solutions for companies developing vaccines, proteins and diagnostics, have formed a license agreement for the development of advanced formulations of vaccines that combine Arecor's formulation technologies with GSK's proprietary vaccines. The companies have collaborated in order to create new approaches that could provide improvements to how several vaccines currently in development are administered. While GSK will gain a license to Arecor's technology, Arecor will in turn receive payments based on development milestones, as well as royalties on sales. Additional details were not disclosed. Tom Saylor, CEO of Arecor, said in a press release that the company is "pleased to work closely" with GSK. "The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilization to specific projects with GSK," said Saylor.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.